Læknablaðið - 15.06.1998, Blaðsíða 39

LÆKNABLAÐIÐ 1998; 84
489
Þakkir
Rannsóknin var styrkt að hluta af Vísinda-
sjóði Landspítalans.
HEIMILDIR
1. World Health Organization, Geneva: Weekly Epidemiolo-
gical Record 1996; 71: 361-8.
2. Briem H. Tölulegar upplýsingar frá landlæknisembætti,
31. des. 1996.
3. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA,
Deutsch P, et al. Viral dynamics in human immunodefí-
ciency virus type 1 infection. Nature 1995; 373: 117-22.
4. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA,
Coombs RW, Poscher ME, et al. HIV viral load markers in
clinical practice. Nat Med 1996; 2: 625-9.
5. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS,
Kokka RP, et al. Quantitation of HIV-1 RNA in plasma
predicts outcome after seroconversion. Ann Intern Med
1995; 122: 573-9.
6. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A,
Benoit S, Rubin M, et al. Changes in plasma HIV-1 RNA
and CD4+ lymphocyte counts and the risk of progression
to AIDS. NEJM 1996; 334: 426-31.
7. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA,
Kingsley LA. Prognosis in HIV-1 infection predicted by
the quantity of virus in plasma. Science 1996; 272: 1167-
70.
8. Revets H, Marissens D, De Wit S, Lacor P, Clumeck N,
Lauwers S. Comparative evaluation of NASBA HIV-1
RNA QT, Amplicor HIV Monitor, and Quantiplex HIV
RNA assay, three methods for quantifícation of human
immunodeficiency virus type 1 RNA in plasma. J Clin
Micro 1996; 34: 1058-64.
9. Lin HJ, Myers LE, Yen-Lieberman B, Hollinger FB, Hen-
rad D, Hooper CJ. Multicenter evaluation of quantifi-
cation methods for plasma human immunodeficiency
virus type RNA. J Infect Dis 1994; 170: 553-62.
10. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jac-
obsen DM, Katzenstein DA, et al. Antiretroviral therapy
for HIV infection in 1996 (Consensus Statement). JAMA
1996; 276: 146-54.
11. Concorde coordinating committee. Concorde MRC/ANRS
randomized double-blind controlled trial of immediate
and deferred zidovudine in symptomfree HIV infection.
Lancet 1994, 343: 871-81.
12. Raboud JM, Haley L, Montaner JS, Murphy C, Januszow-
ska M, Schechter MT, et al. Quantification of the variation
due to laboratory and physiologic sources in CD4+ lymp-
hocyte counts of clinically stable HIV infected indivi-
duals. J Aquir Imm Def Syndr Hum Retrov 1995;
10/Suppl. 2: 67-73.
13. Hoover DR, Graham NM, Chen B, Taylor JM, Phair J,
Zhou SY, et al. Effect of CD4+ cell count measurement
variability on staging HIV-1 infection. J AIDS 1992, 5:
794-802.
14. Cohen C, Sun E, Cameron W, McMahon D. Farthing C,
Poretz D, et al. Ritonavir-Saquinavir combination treat-
ment in HlV-infected patients. Interscience conference on
antimicrobial agents and chemotherapy, New Orleans,
Sept 15-18, 1996; Late breaker abstract 7b.
15. Mccrea J, Buss N, Stone J, Carides A, Dru J, Stewart F, et
al. Indinavir-Saquinavir single dose pharmacokinetic
study. 4th conference on retroviruses and opportunistic
infections, Washington DC, Jan 22-26, 1997; abstract 608
(session 64): 177.
16. Kravick S, Sahai J, Kerr B. Anderson R, Buss N, Seguin I,
et al. Nelfinavir mesylate increases saquinavir-soft gel
capsule exposure in HIV+ patients. 4th conference on
retroviruses and opportunistic infections, Washington DC,
Jan 22-26, 1997; abstract 371 (session 39): 132.
17. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1
protease inhibitors. A review for clinicians. JAMA 1997;
277: 145-53.
18. Powderly WG, Sension M, Conant M, Stein A, Clende-
ninn N. The efficacy of Viracept (nelfinavir mesylate,
NFV) in pivotal phase I/II double-blind randomized con-
trolled trials as monotherapy and in combination with d4T
or AZT/3TC. In: Program and abstracts of the Fourth
Conference on Retroviruses and Opportunistic Infections;
January 22-26, 1997; Washington, DC. Abstract 370.
19. Markowitz M, Cao Y, Vesanen M, Talal A, Nixon D,
Hurley A, et al. Recent HIV infection treated with AZT,
3TC, and a potent protease inhibitor. In: Program and ab-
stracts of the Fourth Conference on Retroviruses and
Opportunistic Infections; January 22-26, 1997; Washing-
ton DC. Abstract LB8.
20. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB,
Burckhardt J, et al. Safety and activity of saquinavir in
HIV infection. Lancet 1995; 345: 952-5.
21. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu
A, Valdes JM, et al. A preliminary study of ritonavir, an
inhibitor of HIV-1 protease, to treat HIV-1 infection.
NEJM 1995; 333: 1534-9.
22. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F,
Gonzales J, et al. A short-term study of the safety, pharma-
cokinetics, and effícacy of ritonavir, an inhibitor of HIV-1
protease. NEJM 1995; 333: 1528-33.
23. Chiasson MA, Berenson L, Li W, Schwarts S, Mojica B,
Hamburg M. Declining AIDS mortality in New York City
(NY). 4th conference on retroviruses and opportunistic
infections, Washington DC, Jan 22-26, 1997. Abstr. 376;
session 40: 133.
24. Mouton Y, Cartier F, Dellamonica P, Humbert G, Lang
JM, Massip P, et al. Dramatic cut in AIDS defining events
and hospitalization for patients under protease inhibitors
and tritherapies in 9 AIDS reference centers and 7,931
patients. 4th conference on retroviruses and opportunistic
infections, Washington DC, Jan 22-26, 1997. Abstract
LB12; session 87: 208.